Last update May 15, 2021

Edoxaban Tosilate

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Direct factor Xa inhibitor, indicated in the prevention and treatment of thromboembolism.
Administered orally once daily.ç

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic characteristics (moderately elevated molecular weight and large volume of distribution) make it very unlikely its excretion into breast milk in significant amounts.

Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable (Daei 2021, Cohen 2016, Bates 2012), especially during the neonatal period and in cases of prematurity.

Alternatives

  • Acenocoumarol (Safe product and/or breastfeeding is the best option.)
  • Dabigatran etexilate (Safe product and/or breastfeeding is the best option.)
  • Dalteparin Sodium (Safe product and/or breastfeeding is the best option.)
  • Enoxaparin Sodium (Safe product and/or breastfeeding is the best option.)
  • Heparin (Safe product and/or breastfeeding is the best option.)
  • Rivaroxaban (Safe product and/or breastfeeding is the best option.)
  • Warfarin (Safe product and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Edoxaban Tosilate in other languages or writings:

Groups

Edoxaban Tosilate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Edoxaban Tosilate in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 62 %
Molecular weight 720 daltons
Protein Binding 55 %
VD 1.5 l/Kg
pKa 10.7 -
Tmax 1 - 2 hours
T½ 10 - 14 hours

References

  1. Daei M, Khalili H, Heidari Z. Direct oral anticoagulant safety during breastfeeding: a narrative review. Eur J Clin Pharmacol. 2021 May 8. Abstract
  2. EMA. Edoxabán (Lixiana). Ficha técnica. 2020 Full text (in our servers)
  3. Cohen H, Arachchillage DR, Beyer-Westendorf J, Middeldorp S, Kadir RA. Direct Oral Anticoagulants and Women. Semin Thromb Hemost. 2016 Oct;42(7):789-797. Epub 2016 Oct 5. Review. Abstract
  4. FDA. Edoxaban (Savaysa). Drug Summary. 2015 Full text (in our servers)
  5. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e691S-e736S. Abstract Full text (link to original source)

Total visits

2,881

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM